Transferator (TRAN) Q2 2024 earnings summary

Executive summary

• Net income for H1 2024 reached 39.4 MSEK, up from 22.2 MSEK year-over-year, mainly due to additional purchase price from the sale of ELKAB Studios.

• Revenue for H1 2024 was 27.6 MSEK, slightly down from 29.2 MSEK in H1 2023.

• EBITDA for H1 2024 was 2.2 MSEK, compared to 2.6 MSEK in the prior year period.

• Dividend of 0.42 SEK per share (totaling 40.4 MSEK) was paid in June 2024.

• Unrealized write-downs of -6.3 MSEK on financial assets negatively impacted results, mainly related to Hedera Group and EMPE Diagnostics.

Financial highlights

• Operating income (EBITDA) for H1 2024 was 2.2 MSEK, down from 2.6 MSEK year-over-year.

• Net financial items contributed 40.7 MSEK, up from 22.7 MSEK in H1 2023.

• Net income per share for H1 2024 was 0.41 SEK, up from 0.24 SEK in H1 2023.

• Equity per share was 0.54 SEK at period end, compared to 0.56 SEK a year earlier.

• Cash and equivalents at period end were 20.3 MSEK.

Outlook and guidance

• Underlying demand for energy storage solutions remains strong, with new market segments reached post-summer.

• Q-linea, a portfolio company, received FDA approval for its instrument and began winning tenders in Europe and placing orders in the US.